If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
<br /> Mesoblas<br /> Annual Re<br /> <br /> t Limited<br /> port 2009 <br /> <br /> <br /> Contents Page<br /> Message from the Chairman 1<br /> Executive Director’s Report 2<br /> Directors’ Report 8<br /> Auditors’ Independence Declaration 25<br /> Corporate Governance 26<br /> Financial Statements 33<br /> Directors’ Declaration 67<br /> Independent Audit Report
MesoblasAnnual Ret Limitedport 2009
MesoblasAnnual Ret Limitedport 2009
Contents
Contents
Message from the ChairmanOn behalf of Mes
Message from the ChairmanOn behalf of Mes
Executive Director’s ReportThe Year in Re
Executive Director’s ReportThe Year in Re
Development of a Global Spinal FranchiseInterver
Development of a Global Spinal FranchiseInterver
Bone Marrow Aspirateand Wisconsin, is co
Bone Marrow Aspirateand Wisconsin, is co
Identification of MPC
Identification of MPC
• Continued evaluation of the safety and effectiv
• Continued evaluation of the safety and effectiv
Pictured at the awards ceremony (l-and Profess
Pictured at the awards ceremony (l-and Profess
Directors’ ReportThe Board of Directors of
Directors’ ReportThe Board of Directors of
Key AchievementsDevelopment of a global spinal f
Key AchievementsDevelopment of a global spinal f
In the first instance, Mesoblast aims to make its
In the first instance, Mesoblast aims to make its
FundingIn April this year, Mesoblast Limited suc
FundingIn April this year, Mesoblast Limited suc
Investment In Angioblast Systems, Inc.Mesoblast
Investment In Angioblast Systems, Inc.Mesoblast
Significant Changes in the State of AffairsNo si
Significant Changes in the State of AffairsNo si
Information on DirectorsBrian Jamieson, Non-exe
Information on DirectorsBrian Jamieson, Non-exe
Byron McAllister, Non-executive Director – BS M.A
Byron McAllister, Non-executive Director – BS M.A
Meetings of DirectorsThe number of meetings of t
Meetings of DirectorsThe number of meetings of t
Remuneration ReportThe directors of the Comp
Remuneration ReportThe directors of the Comp
Relationship between remuneration policy and comp
Relationship between remuneration policy and comp
B.Remuneration of Key Management PersonnelDetail
B.Remuneration of Key Management PersonnelDetail
Details of the remuneration of each director of M
Details of the remuneration of each director of M
Sharebased payments Other
Sharebased payments Other
C. Service AgreementsThe non-executive directors
C. Service AgreementsThe non-executive directors
D. Share-Based CompensationOptions to purchase f
D. Share-Based CompensationOptions to purchase f
Value of options issued to directors and key mana
Value of options issued to directors and key mana
PricewaterhouseCoopersABN 52 780 433 757Freshw
PricewaterhouseCoopersABN 52 780 433 757Freshw
Corporate GovernanceMesoblast Limited (t
Corporate GovernanceMesoblast Limited (t
The term in office held by each Director in offic
The term in office held by each Director in offic
Nerve root nowdecompressed
Nerve root nowdecompressed
MPCs addedMesoblast
MPCs addedMesoblast
Mesoblast
Mesoblast
Mesoblast
Mesoblast
32
32
Financ atementsfor the ye 30 Jun
Financ atementsfor the ye 30 Jun
Income Statementfor the year ended 30 June 2009
Income Statementfor the year ended 30 June 2009
Statement of Changes in Equityfor the year ended
Statement of Changes in Equityfor the year ended
Balance Sheetas at 30 June 2009Note
Balance Sheetas at 30 June 2009Note
Cash Flow Statementfor the year ended 30 June 20
Cash Flow Statementfor the year ended 30 June 20
Notes to the Financial Statementsfor the year en
Notes to the Financial Statementsfor the year en
1. SIGNIFICANT ACCOUNTING POLICIES CONTINUEDGoi
1. SIGNIFICANT ACCOUNTING POLICIES CONTINUEDGoi
1. SIGNIFICANT ACCOUNTING POLICIES CONTINUED(b)
1. SIGNIFICANT ACCOUNTING POLICIES CONTINUED(b)
1. SIGNIFICANT ACCOUNTING POLICIES CONTINUED(g)
1. SIGNIFICANT ACCOUNTING POLICIES CONTINUED(g)
1. SIGNIFICANT ACCOUNTING POLICIES CONTINUED(k)
1. SIGNIFICANT ACCOUNTING POLICIES CONTINUED(k)
1. SIGNIFICANT ACCOUNTING POLICIES CONTINUED(p)
1. SIGNIFICANT ACCOUNTING POLICIES CONTINUED(p)
(v) New and revised accounting standards and inte
(v) New and revised accounting standards and inte
30 June 30 June
30 June 30 June
3. SEGMENT INFORMATION(a) Description of segmen
3. SEGMENT INFORMATION(a) Description of segmen
3. SEGMENT INFORMATION CONTINUED(c) Segment rec
3. SEGMENT INFORMATION CONTINUED(c) Segment rec
4. INCOME TAX EXPENSE(a) Reconciliation of incom
4. INCOME TAX EXPENSE(a) Reconciliation of incom
6. EARNINGS PER SHARENet loss used in calculatin
6. EARNINGS PER SHARENet loss used in calculatin
10. INVESTMENTS ACCOUNTED FOR USING THE EQUITY ME
10. INVESTMENTS ACCOUNTED FOR USING THE EQUITY ME
30 June 30 June
30 June 30 June
13. ISSUED CAPITALOrdinary shares participate i
13. ISSUED CAPITALOrdinary shares participate i
30 June 30 June
30 June 30 June
30 June 30 June
30 June 30 June
18. SHARE-BASED PAYMENTSThe Company has adopted
18. SHARE-BASED PAYMENTSThe Company has adopted
18. SHARE-BASED PAYMENTS CONTINUED(a) Existing
18. SHARE-BASED PAYMENTS CONTINUED(a) Existing
18. SHARE-BASED PAYMENTS CONTINUED(a) Existing
18. SHARE-BASED PAYMENTS CONTINUED(a) Existing
18. SHARE-BASED PAYMENTS CONTINUED(a) Existing
18. SHARE-BASED PAYMENTS CONTINUED(a) Existing
18. SHARE-BASED PAYMENTS CONTINUED(b) Fair valu
18. SHARE-BASED PAYMENTS CONTINUED(b) Fair valu
18. SHARE-BASED PAYMENTS CONTINUED(d) Share opt
18. SHARE-BASED PAYMENTS CONTINUED(d) Share opt
19. KEY MANAGEMENT PERSONNEL COMPENSATION CONTINU
19. KEY MANAGEMENT PERSONNEL COMPENSATION CONTINU
19. KEY MANAGEMENT PERSONNEL COMPENSATION CONTINU
19. KEY MANAGEMENT PERSONNEL COMPENSATION CONTINU
20. RELATED PARTY TRANSACTIONS(a) Equity intere
20. RELATED PARTY TRANSACTIONS(a) Equity intere
20. RELATED PARTY TRANSACTIONS CONTINUED(c) Tra
20. RELATED PARTY TRANSACTIONS CONTINUED(c) Tra
21. FINANCIAL RISK MANAGEMENT CONTINUED(a) Mark
21. FINANCIAL RISK MANAGEMENT CONTINUED(a) Mark
21. FINANCIAL RISK MANAGEMENT CONTINUED(b) Cred
21. FINANCIAL RISK MANAGEMENT CONTINUED(b) Cred
Directors’ DeclarationIn accordance wit
Directors’ DeclarationIn accordance wit
PricewaterhouseCoopersABN 52 780 433 757Indepe
PricewaterhouseCoopersABN 52 780 433 757Indepe
Independent auditor’s report to the members ofMe
Independent auditor’s report to the members ofMe
Shareholder InformationA. SUBSTANTIAL S
Shareholder InformationA. SUBSTANTIAL S
D. TWENTY LARGEST HOLDERS OF QUOTED SECURITIEST
D. TWENTY LARGEST HOLDERS OF QUOTED SECURITIEST
Mesoblast Limited ABN 68 109 431 870Board of Dir
Mesoblast Limited ABN 68 109 431 870Board of Dir